Sign In
Buy CCXI
$10.24
+0.0150 (+0.147%)
At Close: Jun 03, 2026
Churchill Capital Corp XI Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing February 9, 2026
04:28pm, Thursday, 05'th Feb 2026
New York, NY, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Churchill Capital Corp XI (Nasdaq: CCXIU) (the “Company”) announced today that, commencing February 9, 2026, holders of the units sold in the Compan
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX
09:05am, Thursday, 20'th Oct 2022
TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, 2022 /PRNewswire/ -- Amgen
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS ® (avacopan) for patients with ANCA-associated vasculitis; additional poster wil
Is ChemoCentryx (CCXI) Stock Outpacing Its Medical Peers This Year?
11:17am, Thursday, 06'th Oct 2022
Here is how ChemoCentryx (CCXI) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year.
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS,
NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officer
Cancer-Drug Maker's Solid Position And Successful Drug Record Drive Growth
05:09pm, Thursday, 08'th Sep 2022
Cancer-drug maker Amgen solidified its position in a highly competitive market by acquiring its rival Mirati Therapeutics.
Why Is ChemoCentryx (CCXI) Up 1.4% Since Last Earnings Report?
12:48pm, Wednesday, 07'th Sep 2022
ChemoCentryx (CCXI) reported earnings 30 days ago. What's next for the stock?
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates ONEM, CCXI, AERI, SFT
11:26am, Thursday, 25'th Aug 2022
NEW YORK , Aug. 25, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches
ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences
08:30am, Wednesday, 24'th Aug 2022
SAN CARLOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned poster presentations at three upcoming medical conferences taking place in August and
Here's Why ChemoCentryx (CCXI) is a Great Momentum Stock to Buy
01:33pm, Tuesday, 16'th Aug 2022
Does ChemoCentryx (CCXI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Get ready for more merger mania in pharma sector the rest of the year
02:43pm, Tuesday, 09'th Aug 2022
Pfizer Inc.'s PFE, +0.24% $5.4 billion acquisition of Global Blood Therapeutics Inc. GBT, +0.02% is the latest sign that cash-flush drug makers are ready to jump back into dealmaking.
Shareholder Alert - The M&A Class Action Firm Announces the Investigation of ChemoCentryx, Inc. - CCXI
01:58pm, Tuesday, 09'th Aug 2022
NEW YORK , Aug. 9, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rat
ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call
08:30am, Tuesday, 09'th Aug 2022
SAN CARLOS, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the cancellation of its second quarter 2022 financial results conference call scheduled for Tu
ChemoCentryx (CCXI) Moves 109.2% Higher: Will This Strength Last?
09:02am, Friday, 05'th Aug 2022
ChemoCentryx (CCXI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
